Urol. praxi, 2013; 14(5): 204-211

Novel therapeutic options in prostate cancer before chemotherapy

MUDr.Otakar Čapoun, FEBU
Urologická klinika VFN a 1. LF UK v Praze

Prostate cancer in the stage of castration resistance became a serious medical and socio-economic problem of the new millennium.

The prognosis of patients with this stage is very unfavorable, is associated with a number of painful complications and its treatment is

burdened with numerous side effects. Effective hormone blockade in this stage showed persistence of partial sensitivity of tumor cells

to the effect of testosterone. New hormonal agents (abiraterone, enzalutamide) has been approved for use in the second-line treatment

after failure of docetaxel and further research is directed to the earlier stages of the disease. Inhibitors of angiogenesis (tasquinimod)

may act synergistically with significant effect even in cases with visceral metastases. Monoclonal antibodies may interfere with the host

immune response against tumor cells. Results of trials with new hormonal drugs or small molecules are not currently available, but their

effectiveness is expected to be confirmed also in the population of chemotherapy-naive patients.

Keywords: castration resistant prostate cancer, abiraterone, enzalutamide, tasquinimod

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čapoun O. Novel therapeutic options in prostate cancer before chemotherapy. Urol. praxi. 2013;14(5):204-211.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mužík J, Dušek L, Babjuk M, Kubásek M, Fínek J, Petruželka L. Uroweb - webový portál pro analýzu a vizualizaci epidemiologie, diagnostiky a léčby urologických malignit [online]. Masarykova univerzita, Brno, 2013. [cit. 2013-0629]. Dostupný z WWW: http://www.uroweb.cz. ISSN 18046371. Verze 1.6d.
    2. Mottet N, Bellmunt J, Bolla M, et al. EAU Guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011; 59 (4): 572-583. Go to original source... Go to PubMed...
    3. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21(7): 1232-1237. Go to original source... Go to PubMed...
    4. Humphreys MR, Fernandes KA, Sridhar SS. Impact of age at diagnosis on outcomes in men with castrate-resistant prostate cancer (CRPC). J Cancer. 2013; 4(4): 304-314. Go to original source... Go to PubMed...
    5. Omlin A, et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol (2013), http://dx.doi.org/10.1016/j.eururo.2012.12.029. Go to original source... Go to PubMed...
    6. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26(7): 1148-1159. Go to original source... Go to PubMed...
    7. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26(2): 242-245. Go to original source... Go to PubMed...
    8. Eisenberger M, Garrett-Mayer ES, Ou Yang Y, et al. Multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC). J Clin Oncol 25, 2007 (suppl; abstr 5058). Go to original source...
    9. Lissbrant IF, Garmo H, Widmark A, Stattin P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013 Feb 21. Go to original source... Go to PubMed...
    10. Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009; 55: 1368-1375. Go to original source... Go to PubMed...
    11. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13(10): 983-992. Go to original source... Go to PubMed...
    12. http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf. Přístup 22. 6. 2013.
    13. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368(2): 138-148. Go to original source... Go to PubMed...
    14. National Cancer Institute at the National Institutes of Health. FDA approval for abiraterone acetate [online], http://www.cancer.gov/cancertopics/druginfo/fda-abirateroneacetate. Přístup 22. 6. 2013.
    15. Rathkopf DE, Smith MR, deBono JS. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. J Clin Oncol 31, 2013 (suppl 6; abstr 5). Go to original source...
    16. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324(5928): 787-790. Go to original source... Go to PubMed...
    17. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375(9724): 1437-1446. Go to original source... Go to PubMed...
    18. Katolická J. Komentář ke studii Enzalutamid v terapii pacientů s karcinomem prostaty rezistentním vůči kastraci - studie AFFIRM. Farmakoterapie, 2013; 9(2): 163.
    19. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13): 1187-1197. Go to original source... Go to PubMed...
    20. Medivation and Astellas Provide Update on PREVAIL [press release]. San Francisco, CA and Tokyo, Japan - April 1, 2013. http://www.astellas.com/en/corporate/news/pdf/130402_1_Eg.pdf. Přístup 24. 6. 2013.
    21. Jain RK, Au P, Tam J, et al. Engineering vascularized tissue. Nat Biotechnol. 2005; 23(7): 821-823. Go to original source... Go to PubMed...
    22. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration resistant prostate cancer: CALGB 90401. Journal of Clinical Oncology 2012; 30: 1534-1540. Go to original source... Go to PubMed...
    23. Mukherji D, Temraz S, Wehbe D, Shamseddine A. Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol. 2013 Jan 29. Go to original source... Go to PubMed...
    24. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology. 2000; 54(9): 1734-1741. Go to original source... Go to PubMed...
    25. Isaacs JT, Pili R, Qian DZ, et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006; 66(16): 1768-1778. Go to original source... Go to PubMed...
    26. Kallberg E, Vogl T, Liberg D, et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS One. 2012; 7(3): e34207. Go to original source... Go to PubMed...
    27. Isaacs JT, Antony L, Dalrymple SL, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013; 73(4): 1386-1399. Go to original source... Go to PubMed...
    28. Williamson SC, Hartley AE, Heer R. A review of tasquinimod in the treatment of advanced prostate cancer. Drug Des Devel Ther. 2013; 7: 167-174. Go to original source... Go to PubMed...
    29. Bratt O, Häggman M, Ahlgren G, et al. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer. 2009; 101(8): 1233-1240. Go to original source... Go to PubMed...
    30. Pili R, Häggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011; 29(30): 4022-4028. Go to original source... Go to PubMed...
    31. A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer. [ClinicalTrials.gov Identifier: NCT01234311]. US National Institutes of Health. http://clinicaltrials.gov. Přístup dne 23. 6. 2013.
    32. Multi-Center Phase II Study to Compare MER-101 20 mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients. [ClinicalTrials.gov Identifier: NCT00636740]. US National Institutes of Health. http://clinicaltrials.gov. Přístup dne 30. 6. 2013.
    33. Bartůňková, J, Špíšek R, Podrazil M. Imunoterapie karcinomu prostaty. Urol. praxi, 2013; 14(1): 15-18.
    34. George DJ, Corn PG, Michaelson MD, et al. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmcrpc) and rising prostate-specific antigen (psa): updated results of a phase II study. J Clin Oncol 30, 2012 (suppl; abstr 4549). Go to original source...
    35. Rathkopf D, Danila D, Morris M, et al. Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): phase I results of a Prostate Cancer Clinical Trials Consortium study. J Clin Oncol 30, 2012 (suppl; abstr 4548). Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.